Biotech Values

[vinmantoo]

And what if no one partners?

Seriously?? I expect better from you jbog. You can't actually need me to tell you the two options? I already wrote one of them.

You can certainly feel that EDP-235 is a dead end and that ENTA won't be able to get a partner but that is distinct from the point I am making.

Do you understand what dead end means if they won't be able to get a partner?

The second option is also obvious. If extensive attempts to secure a partner fails to get one, or at least a partner at what they consider reasonable terms, then ENTA could explore the feasibility of running a phase 3 themselves. In that scenario they would consult with the FDA about how to run the phase 3 trial, and then figure out the cost. At that point they would have to decide whether to take the plunge.